Search for a trial

Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study

This study has been transitioned to CTIS with ID 2023-508478-27-00 check the CTIS register for the current data. The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET results in improved efficacy…

Interactions between tumor cells and lymphocytes in classical Hodgkin lymphoma

To study the interaction between normal T lymphocytes and Hodgkin tumor cells in an in vitro model.

Phase I/II feasibility study combining Brentuximab Vedotin (Adcetris) with second line salvage chemotherapy (DHAP) in Hodgkin lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous peripheral blood stem cell transplantation

To increase the fraction of patients with a PET-negative metabolic complete remission after second line chemotherapy with 3 courses of DHAP , each in combination with one i.v infusion of BV. This will make more patients eligible for high dose…

Development of blood-based monitoring techniques in lymphatic malignancies

Development of blood-based monitoring techniques for treatment response evaluation and diagnostics in lymphoid neoplasms, including HL and NHL by using extracellular vesicle and cfDNA techniques for biomarker discovery, assay development and…

TARC-002 EVALUATION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PATIENTS WITH LYMPHADENOPATHY , FEVER OR NON-HODGKIN LYMPHOMA

To evaluate TARC in patients with fever, lymphadenopathy or non-Hodgkin lymphoma